Cellebrite DI Ltd. Investigation - CLBT

Company
Cellebrite DI Ltd. (NASDAQ: CLBT)

Learn more about the Cellebrite DI Ltd. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Cellebrite DI Ltd. Investigation Details

Cellebrite DI Ltd. shares fell after the Company reported a weaker forward-growth message in its quarterly earnings report, disappointing investors despite third-quarter revenue of approximately $149 million exceeding FactSet estimates. During the quarter, annual recurring revenue (ARR) grew 20% and adjusted EBITDA guidance was raised, but the Company trimmed full-year revenue guidance again and guided fourth-quarter revenue to $145 million to $150 million. Previously, during an August 13, 2026 earnings call for the second quarter of 2026, Chief Executive Officer Shiven Ramji addressed performance, stating, "We did not deliver the ARR and revenue performance we expected in the second quarter. On our last call, we expected a meaningful acceleration in Q2. That acceleration did not materialize at the level we anticipated, and we own that." CEO Shiven Ramji also cautioned investors that "Pipeline is not performance." On the same call, Chief Financial Officer David Barter stated, "We've lowered our full year 2026 ARR guidance range to $550 million to $560 million, a reduction of $15 million at the midpoint." Additionally, SEC filings showed prior clerical corrections, such as a Form 20-F/A filed April 12, 2024, correcting a typographical error in a share-price trigger threshold from $30.00 to $17.50. The investigation concerns whether Cellebrite DI Ltd. adequately disclosed its revenue growth trends and full-year ARR guidance reductions ahead of its forward-looking guidance updates.

Get Started